U.S. court invalidates patent on Bristol hepatitis B drug

Tue Feb 12, 2013 9:54am EST

Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.

"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.